Uncategorized

Life Science CEOs “Upbeat” About Industry Prospects

Read more

NPAs and DPAs – An Enforcement Loophole or Compliance Incentive?

Read more

Is Pricing the New Frontier?

Read more

The Debate Rages On: Should Clinical Trial Data Be Public?

Read more

FDA Criticized for Moving Too Slowly

Read more

ClinRegs Upgrades Are Here!

Read more

FDA Announces Dates for Public Hearing on Off-Label Communication Regulation

Read more

Novartis CEO Predicts Shift in Drug Pricing, Post-Election

Read more

Mylan CEO Under Fire at House Hearing

Read more

PDUFA IV: Full Steam Ahead?

Read more